- Home
- UFCS vs KROS Comparison
UFCS vs KROS Comparison
Compare UFCS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- KROS
- Stock Information
- Founded
- UFCS 1946
- KROS 2015
- Country
- UFCS United States
- KROS United States
- Employees
- UFCS N/A
- KROS N/A
- Industry
- UFCS Property-Casualty Insurers
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- KROS Health Care
- Exchange
- UFCS Nasdaq
- KROS Nasdaq
- Market Cap
- UFCS 642.7M
- KROS 460.6M
- IPO Year
- UFCS N/A
- KROS 2020
- Fundamental
- Price
- UFCS $24.95
- KROS $11.00
- Analyst Decision
- UFCS Hold
- KROS Buy
- Analyst Count
- UFCS 1
- KROS 11
- Target Price
- UFCS $26.00
- KROS $45.33
- AVG Volume (30 Days)
- UFCS 132.1K
- KROS 2.1M
- Earning Date
- UFCS 02-11-2025
- KROS 02-26-2025
- Dividend Yield
- UFCS 2.56%
- KROS N/A
- EPS Growth
- UFCS N/A
- KROS N/A
- EPS
- UFCS 1.94
- KROS N/A
- Revenue
- UFCS $1,207,451,000.00
- KROS $651,000.00
- Revenue This Year
- UFCS N/A
- KROS $303.27
- Revenue Next Year
- UFCS $11.31
- KROS N/A
- P/E Ratio
- UFCS $12.86
- KROS N/A
- Revenue Growth
- UFCS 10.95
- KROS 8037.50
- 52 Week Low
- UFCS $18.04
- KROS $9.78
- 52 Week High
- UFCS $31.70
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- UFCS 34.07
- KROS 24.79
- Support Level
- UFCS $24.11
- KROS $11.04
- Resistance Level
- UFCS $26.15
- KROS $11.99
- Average True Range (ATR)
- UFCS 0.82
- KROS 0.60
- MACD
- UFCS -0.05
- KROS 1.20
- Stochastic Oscillator
- UFCS 25.15
- KROS 43.99
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.